Open an account

Exousia Pro

MAJI · OTC

$0.0038+$0.0004 (+11.76%)TodayMarket closed ·
Prev close $0.0034

About MAJI

Marijuana, Inc. operates as a shell company seeking to merge with another entity with experienced management and opportunities for growth. The company is headquartered in Saint Petersburg, Florida. The company went IPO on 2010-12-28. The firm's mammalian exosomal technology platform has shown the capability to increase the efficacy of Merck's drug Temozolomide (TMZ) in the treatment of glioblastoma (GBM). Its patented manufacturing process utilizes plant-based materials to create exosomes used in a number of commercial applications from dermatology to dentistry. The firm's proprietary loading technology can infuse a range of molecules from drugs to deoxyribonucleic acid (DNA).

Employees
0
Headquarters
Saint Petersburg, Florida
Listed
Dec 28, 2010
Sector
Health Care
Industry
Biotechnology
Website
exousiapro.com

MAJI key statistics

Market cap
322.95K
Price-earnings ratio
—
Dividend yield
—
Average volume
828.79K
Volume
1.66M
Open price
$0.0032
High today
$0.0038
Low today
$0.0031
52 Week high
$0.15
52 Week low
$0.0017

Exousia Pro (MAJI) at a glance

Exousia Pro (MAJI) last traded at $0.0038, with a market cap of 322.95K.

Today the stock has traded between $0.0031 and $0.0038. The current price is 22.6% above the day's low and 0.0% below its high.

Volume so far is 1.66M shares, above the average of 828.79K shares a day.

Over the past year Exousia Pro has ranged from $0.0017 to $0.15, and now sits 1% of the way up that range.

MAJI news

  • Press releaseACCESS Newswire

    NexTel Medical Corp. Announces Next-Generation Wellness Product Line Incorporating FDA-Approved Pharmaceuticals

  • Press releaseACCESS Newswire

    NexTel Medical Corp. Announces Strategic Joint Venture to Commercialize Breakthrough Patented Hair Regeneration Technology

  • Press releaseACCESS Newswire

    NexTel Medical Corp. Showcases Pioneer Exosome Technologies and Diagnostic Innovations at Leading Healthcare Conference

  • Press releaseACCESS Newswire

    NexTel Medical Corp. Advances Veterinary Oncology Strategy with Rollout of Early-Stage Cancer Screening for Companion Animals

  • Press releaseGlobe Newswire

    NexTel Medical Corp. Amends Previously Announced Acquisition to Acquire Island 40 Group and Full Subsidiary Platform

  • Press releaseGlobe Newswire

    NexTel Medical Corp. Announces Groundbreaking, First-of-Its-Kind Exosome Characterization Study with Penn State University

  • Press releaseGlobe Newswire

    NexTel Medical Corp. Executes Definitive Purchase Agreements to Acquire JumpstartRx and NueVistraMed, Expanding Telehealth Footprint and Accelerating Maxasome™ Commercialization

  • Press releaseGlobe Newswire

    NexTel Medical Corp Enters Final Stage for Commercial Launch; Sets Sights on Revenue Generation and OTCQB Uplist

Similar companies

Companies in the same industry as Exousia Pro

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.